Alector, Inc. Files 8-K on Exit Costs and Disclosures
Ticker: ALEC · Form: 8-K · Filed: Nov 25, 2024 · CIK: 1653087
| Field | Detail |
|---|---|
| Company | Alector, INC. (ALEC) |
| Form Type | 8-K |
| Filed Date | Nov 25, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $3.9 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, disposal-activities, financials
TL;DR
ALEC filing 8-K: Exit costs, Reg FD, financials. What's going on?
AI Summary
On November 25, 2024, Alector, Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing also included Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in South San Francisco, California.
Why It Matters
This filing indicates potential restructuring or divestiture activities within Alector, Inc., which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Disclosures about exit or disposal activities can signal significant business changes that may carry financial and operational risks.
Key Players & Entities
- Alector, Inc. (company) — Registrant
- November 25, 2024 (date) — Date of Report
- South San Francisco, California (location) — Principal Executive Offices
- Delaware (location) — State of Incorporation
FAQ
What specific activities are associated with the 'Cost Associated with Exit or Disposal Activities'?
The filing does not specify the exact nature of the exit or disposal activities, but it is reported under Item 2.05 of the 8-K.
What is the purpose of the Regulation FD Disclosure mentioned in the filing?
The Regulation FD Disclosure (Item 7.01) is included to ensure that material non-public information is broadly disseminated to the public, preventing selective disclosure.
What financial statements and exhibits are included with this 8-K filing?
The filing indicates that Financial Statements and Exhibits are included as Item 9.01, but the specific contents are not detailed in the provided text.
When was Alector, Inc. formerly known as Alector LLC, and when did the name change occur?
Alector, Inc. was formerly known as Alector LLC, with the date of the name change being September 15, 2015.
What is Alector, Inc.'s Standard Industrial Classification (SIC) code and industry?
Alector, Inc.'s SIC code is 2836, which corresponds to the 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' industry.
Filing Stats: 1,033 words · 4 min read · ~3 pages · Grade level 12.9 · Accepted 2024-11-25 16:10:07
Key Financial Figures
- $3.9 m — force are expected to be approximately $3.9 million, primarily consisting of personne
Filing Documents
- alec-20241125.htm (8-K) — 45KB
- alec-ex99_1.htm (EX-99.1) — 24KB
- img61176764_0.jpg (GRAPHIC) — 27KB
- 0000950170-24-130564.txt ( ) — 223KB
- alec-20241125.xsd (EX-101.SCH) — 24KB
- alec-20241125_htm.xml (XML) — 5KB
05 Costs Associated with Exit or Disposal Activities
Item 2.05 Costs Associated with Exit or Disposal Activities. On November 25, 2024, Alector, Inc. ("Alector" or "the Company") committed to a plan to reduce its workforce (the "Plan") by approximately 17% in order to align resources with the Company's strategic priorities. Based upon the results of the Company's INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in early Alzheimer's disease, the Company is stopping the long term extension of the INVOKE-2 study. The Company initiated a reduction in force impacting approximately 41 employees across the organization. The Company continues to expect that its existing cash, cash equivalents and investments will enable it to fund its operating expenses and capital expenditure requirements through 2026. One-time restructuring charges associated with the reduction in force are expected to be approximately $3.9 million, primarily consisting of personnel expenses such as salaries, one-time severance payments, and other benefits. Cash payments related to these expenses will be paid out and the reduction in force is expected to be completed during the first half of 2025. The estimated costs that the Company expects to incur in connection with the reduction are subject to a number of assumptions, and actual results may differ significantly from these estimates. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the reduction.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 25, 2024, the Company issued a press release announcing data results from the INVOKE-2 clinical trial evaluating the Company's AL002 product candidate and the Plan described above. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference. The information contained under Item 7.01 of this Current Report (including Exhibit 99.1), shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act except as may be expressly set forth by specific reference in such filing. Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements as that term is defined in Section 27A of the Securities Act and Section 21E of the Exchange Act. Such forward-looking statements involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this Form 8-K are forward-looking statements including statements relating to the Company's plans, expectations, forecasts and future events. Such forward-looking statements include, but are not limited to, the potential of, and expectations regarding the Company's business strategy, statements relating to the anticipated timing and details of the Plan and the expected impacts, charges and costs associated with the Plan that the Company expects to incur. In some cases, you can identify forward-looking statements by terminology such as "believe," "estimate," "intend," "may," "plan," "potentially," "will," "expect," "enable," "likely" or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about futur
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated November 25, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALECTOR, INC. Date: November 25, 2024 By: /s/ Marc Grasso Marc Grasso, M.D. Chief Financial Officer